Suppr超能文献

干细胞疗法治疗慢性肝脏疾病:进展与挑战。

Stem Cell Therapies for Chronic Liver Diseases: Progress and Challenges.

机构信息

Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, People's Republic of China.

The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People's Republic of China.

出版信息

Stem Cells Transl Med. 2022 Sep 21;11(9):900-911. doi: 10.1093/stcltm/szac053.

Abstract

Chronic liver diseases have become a significant health issue worldwide and urgently require the development of novel therapeutic approaches, in addition to liver transplantation. Recent clinical and preclinical studies have shown that cell-based therapeutic strategies may contribute to the improvement of chronic liver diseases and offer new therapeutic options to restore liver function through their roles in tissue impairment and immunomodulation. In this review, we summarize the current progress and analyze the challenges for different types of cell therapies used in the treatment of chronic liver diseases currently explored in clinical trials and preclinical studies in animal models. We also discuss some critical issues regarding the use of mesenchymal stem cells (MSCs, the most extensive cell source of stem cells), including therapeutic dosage, transfusion routine, and pharmacokinetics/pharmacodynamics (PK/PD) of transfused MSCs.

摘要

慢性肝脏疾病已成为全球范围内的重大健康问题,除了肝移植之外,还迫切需要开发新的治疗方法。最近的临床前和临床研究表明,基于细胞的治疗策略可能有助于改善慢性肝脏疾病,并通过其在组织损伤和免疫调节中的作用提供新的治疗选择来恢复肝功能。在这篇综述中,我们总结了目前用于治疗慢性肝脏疾病的不同类型细胞疗法的最新进展,并分析了其在临床试验和临床前动物模型研究中的挑战。我们还讨论了一些关于间充质干细胞(MSC,最广泛的干细胞来源)使用的关键问题,包括治疗剂量、输注常规和输注 MSC 的药代动力学/药效学(PK/PD)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2cf/9492280/f335d7b17087/szac053f0002.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验